news
Broad label FDA approval for phenylketonuria drug
Alongside Phase III data demonstrating significant efficacy in the rare disease, the FDA’s decision could position the small molecule as a future standard of care.
List view / Grid view
phenylketonuria (PKU)
article
Capsosomes: the revolutionary enzyme carriers
Nature can offer inspiration for the synthesis of more effective drug delivery platforms. In this article, Marc Baiget Francesch discusses the potential of capsosomes as a novel, biocompatible, drug delivery system.
news
FDA approves Palynziq for PKU, a rare and serious genetic disease
Novel enzyme therapy for adults with PKU who have uncontrolled blood phenylalanine concentrations with current treatment...
